Doris Leithner
Overview
Explore the profile of Doris Leithner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
810
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Corona M, Ip A, Brown S, Luna A, Khatib H, Flynn J, et al.
Bone Marrow Transplant
. 2025 Feb;
PMID: 39893244
CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has recently been approved as second-line treatment for relapsed/refractory large B-cell lymphoma (LBCL). This study compares patterns of disease relapse and progression across...
2.
Park J, Palomba M, Perica K, Devlin S, Shah G, Dahi P, et al.
J Clin Oncol
. 2025 Jan;
:JCO2402424.
PMID: 39883889
Purpose: We designed a CD19-targeted chimeric antigen receptor (CAR) comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3ζ and 4-1BB/CD3ζ CARs. Preclinical data demonstrated that...
3.
Woo S, Becker A, Leithner D, Mayerhoefer M, Friedman K, Tong A, et al.
Eur Radiol
. 2025 Jan;
PMID: 39853335
Objectives: An increasing number of patients with prostate cancer (PCa) undergo assessment with magnetic resonance imaging (MRI) and prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT). This offers comprehensive multimodality...
4.
Leithner D, Neri E, DAnastasi M, Schlemmer H, Winkelmann M, Kunz W, et al.
Eur Radiol
. 2025 Jan;
PMID: 39747586
Imaging is used for lymphoma detection, Ann Arbor/Lugano staging, and treatment response assessment. [F]FDG PET/CT should be used for most lymphomas, including Hodgkin lymphoma, aggressive/high-grade Non-Hodgkin lymphomas (NHL) such as...
5.
Wray R, Mauguen A, Michaud L, Leithner D, Yeh R, Riaz N, et al.
J Nucl Med
. 2024 Sep;
65(10):1526-1532.
PMID: 39266287
Tumor hypoxia, an integral biomarker to guide radiotherapy, can be imaged with F-fluoromisonidazole (F-FMISO) hypoxia PET. One major obstacle to its broader application is the lack of standardized interpretation criteria....
6.
Hubbeling H, Leithner D, Silverman E, Flynn J, Devlin S, Shah G, et al.
Clin Cancer Res
. 2024 Sep;
30(22):5083-5093.
PMID: 39259292
Purpose: Greater disease burden is a well-established predictor of poorer outcomes following chimeric antigen receptor T-cell (CAR T) therapy. Although bridging therapy (BT) is widely used between leukapheresis and CAR...
7.
Becker A, Woo S, Leithner D, Tong A, Mayerhoefer M, Vargas H
Eur J Radiol
. 2024 Aug;
179:111665.
PMID: 39128251
Aim: To investigate the associations between the hour of the day and Prostate Imaging-Reporting and Data System (PI-RADS) scores assigned by radiologists in prostate MRI reports. Materials And Methods: Retrospective...
8.
Park J, Palomba M, Perica K, Devlin S, Shah G, Dahi P, et al.
Res Sq
. 2024 Jul;
PMID: 39011120
We designed a CD19-targeted CAR comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3z and 4-1BB/CD3z CARs. Here we report the first-in-human, phase 1 clinical...
9.
Mayerhoefer M, Shepherd T, Weber M, Leithner D, Woo S, Pan J, et al.
Invest Radiol
. 2024 Jun;
59(11):782-786.
PMID: 38896439
Objectives: The aim of this study was to determine whether MRI radiomic features of key cerebral structures differ between women and men, and whether detection of such differences depends on...
10.
Asmundo L, Rizzetto F, Blake M, Anderson M, Mojtahed A, Bradley W, et al.
J Clin Med
. 2024 Jun;
13(11).
PMID: 38892992
Neuroendocrine neoplasms (NENs) are a diverse group of tumors with varying clinical behaviors. Their incidence has risen due to increased awareness, improved diagnostics, and aging populations. The 2019 World Health...